Mariner LLC grew its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 15.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,711 shares of the company's stock after acquiring an additional 509 shares during the quarter. Mariner LLC's holdings in argenx were worth $2,283,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Neuberger Berman Group LLC lifted its stake in shares of argenx by 9.5% during the fourth quarter. Neuberger Berman Group LLC now owns 770 shares of the company's stock worth $474,000 after purchasing an additional 67 shares in the last quarter. DRW Securities LLC acquired a new stake in shares of argenx in the 4th quarter valued at about $780,000. Raymond James Financial Inc. bought a new stake in shares of argenx in the 4th quarter valued at approximately $43,543,000. Capula Management Ltd acquired a new position in shares of argenx in the 4th quarter valued at about $1,955,000. Finally, FIL Ltd acquired a new stake in shares of argenx during the 4th quarter worth approximately $38,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have issued reports on ARGX. Wedbush reissued an "outperform" rating and set a $715.00 target price on shares of argenx in a research note on Friday, April 11th. Oppenheimer lifted their target price on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Guggenheim raised their target price on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Finally, Citigroup upped their price target on argenx from $681.00 to $796.00 and gave the company a "buy" rating in a report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $699.28.
Get Our Latest Analysis on argenx
argenx Price Performance
argenx stock traded up $14.25 during trading hours on Friday, hitting $614.76. The company had a trading volume of 215,836 shares, compared to its average volume of 308,133. The firm has a market capitalization of $37.54 billion, a P/E ratio of -698.59 and a beta of 0.60. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21. The firm's fifty day moving average is $598.28 and its 200-day moving average is $608.44.
argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.
argenx Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Recommended Stories
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
